The challenge of cholangiocarcinoma: Dissecting the molecular mechanisms of an insidious cancer

DMM Disease Models and Mechanisms

Volumn 6, Issue 2, 2013, Pages 281-292

  Zabron, Abigail ^a   Edwards, Robert J ^b   Khan, Shahid A ^a  

^a Gastroenterology and Hepatology Research   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; B RAF KINASE; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CALVASCULIN; CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE B; GEMCITABINE; K RAS PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE CELL ADHESION MOLECULE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; URSODEOXYCHOLIC ACID; VASCULOTROPIN A; VASCULOTROPIN C; VIMENTIN;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BILIARY STENT; BILIARY TRACT INFECTION; BILIARY TRACT SURGERY; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER INVASION; CANCER MODEL; CANCER RISK; CANCER SURVIVAL; CASE REPORT; CELL CYCLE REGULATION; CELL PROLIFERATION; CHEMORADIOTHERAPY; CHOLESTASIS; CHRONIC INFLAMMATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FATIGUE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARASITOSIS; PATHOPHYSIOLOGY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION; ULCERATIVE COLITIS; WEIGHT REDUCTION;

ANIMALS; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; HUMANS; RISK FACTORS;

EID: 84875142062     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.010561     Document Type: Article

References (139)

1. Abdel Wahab, M., Mostafa, M., Salah, T., Fouud, A., Kandeel, T., Elshobary, M., Abd Allah, O. F., Elghawalby, N., Sultan, A. and Ezzat, F. (2007). Epidemiology of hilar cholangiocarcinoma in Egypt: single center study. Hepatogastroenterology 54, 1626-1631. (Pubitemid 350068440)
2. Ahrendt, S. A., Rashid, A., Chow, J. T., Eisenberger, C. F., Pitt, H. A. and Sidransky, D. (2000). p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J. Hepatobiliary Pancreat. Surg. 7, 426-431.
3. 2+-, PKC-, and MAPK-dependent pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G973-G982. (Pubitemid 38715660)
4. Araki, K., Shimura, T., Suzuki, H., Tsutsumi, S., Wada, W., Yajima, T., Kobayahi, T., Kubo, N. and Kuwano, H. (2011). E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br. J. Cancer 105, 1885-1893.
5. Bangarulingam, S. Y., Bjornsson, E., Enders, F., Barr Fritcher, E. G., Gores, G., Halling, K. C. and Lindor, K. D. (2010). Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 51, 174-180.
6. Barr Fritcher, E. G., Kipp, B. R., Voss, J. S., Clayton, A. C., Lindor, K. D., Halling, K. C. and Gores, G. J. (2011). Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am. J. Gastroenterol. 106, 2023-2028.
7. Bierie, B. and Moses, H. L. (2006). Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506-520. (Pubitemid 43980540)
8. Blechacz, B. and Gores, G. J. (2008). Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48, 308-321. (Pubitemid 351975555)
9. Blechacz, B., Komuta, M., Roskams, T. and Gores, G. J. (2011). Clinical diagnosis and staging of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 8, 512-522.
10. Braconi, C., Huang, N. and Patel, T. (2010). MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 51, 881-890.
11. Burak, K., Angulo, P., Pasha, T. M., Egan, K., Petz, J. and Lindor, K. D. (2004). Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. 99, 523-526. (Pubitemid 38524134)
12. Campbell, D. J., Dumur, C. I., Lamour, N. F., Dewitt, J. L. and Sirica, A. E. (2012). Novel organotypic culture model of cholangiocarcinoma progression. Hepatol. Res. 42, 1119-1130.
13. Certad, G., Benamrouz, S., Guyot, K., Mouray, A., Chassat, T., Flament, N., Delhaes, L., Coiteux, V., Delaire, B., Praet, M. et al. (2012). Fulminant cryptosporidiosis after near-drowning: a human Cryptosporidium parvum strain implicated in invasive gastrointestinal adenocarcinoma and cholangiocarcinoma in an experimental model. Appl. Environ. Microbiol. 78, 1746-1751.
14. Chapman, M. H., Sandanayake, N. S., Andreola, F., Dhar, D. K., Webster, G. J., Dooley, J. S. and Pereira, S. P. (2011). Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. J. Clin. Exp. Hepatol. 1, 6-12.
15. Chapman, M. H., Tidswell, R., Dooley, J. S., Sandanayake, N. S., Cerec, V., Deheragoda, M., Lee, A. J., Swanton, C., Andreola, F. and Pereira, S. P. (2012). Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. J. Hepatol. 56, 877-885.
16. Chuang, S. C., La Vecchia, C. and Boffetta, P. (2009). Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 286, 9-14.
17. Claessen, M. M., Vleggaar, F. P., Tytgat, K. M., Siersema, P. D. and Van Buuren, H. R. (2009). High lifetime risk of cancer in primary sclerosing cholangitis. J. Hepatol. 50, 158-164.
18. Darwish Murad, S., Kim, W. R., Harnois, D. M., Douglas, D. D., Burton, J., Kulik, L. M., Botha, J. F., Mezrich, J. D., Chapman, W. C., Schwartz, J. J. et al. (2012). Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143, 88-98, e3, quiz e14.
19. Donato, F., Gelatti, U., Tagger, A., Favret, M., Ribero, M. L., Callea, F., Martelli, C., Savio, A., Trevisi, P. and Nardi, G. (2001). Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 12, 959-964. (Pubitemid 34048878)
20. El-Khoueiry, A. B., Rankin, C. J., Ben-Josef, E., Lenz, H. J., Gold, P. J., Hamilton, R. D., Govindarajan, R., Eng, C. and Blanke, C. D. (2012). SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest. New Drugs 30, 1646-1651.
21. El-Serag, H. B., Engels, E. A., Landgren, O., Chiao, E., Henderson, L., Amaratunge, H. C. and Giordano, T. P. (2009). Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U. S. veterans. Hepatology 49, 116-123.
22. Endo, K., Ashida, K., Miyake, N. and Terada, T. (2001). E-cadherin gene mutations in human intrahepatic cholangiocarcinoma. J. Pathol. 193, 310-317. (Pubitemid 32229861)
23. Endo, K., Yoon, B. I., Pairojkul, C., Demetris, A. J. and Sirica, A. E. (2002). ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36, 439-450. (Pubitemid 34810365)
24. Fabris, L., Cadamuro, M., Moserle, L., Dziura, J., Cong, X., Sambado, L., Nardo, G., Sonzogni, A., Colledan, M., Furlanetto, A. et al. (2011). Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology 54, 890-899.
25. Farazi, P. A., Zeisberg, M., Glickman, J., Zhang, Y., Kalluri, R. and De Pinho, R. A. (2006). Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 66, 6622-6627. (Pubitemid 44085618)
26. Farina, A., Dumonceau, J. M., Delhaye, M., Frossard, J. L., Hadengue, A., Hochstrasser, D. F. and Lescuyer, P. (2011). A step further in the analysis of human bile proteome. J. Proteome Res. 10, 2047-2063.
27. Fava, G. (2010). Molecular mechanisms of cholangiocarcinoma. World J. Gastrointest. Pathophysiol. 1, 12-22.
28. Fava, G., Demorrow, S., Gaudio, E., Franchitto, A., Onori, P., Carpino, G., Glaser, S., Francis, H., Coufal, M., Marucci, L. et al. (2009). Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression. Liver Int. 29, 1031-1042.
29. Frampton, G., Invernizzi, P., Bernuzzi, F., Pae, H. Y., Quinn, M., Horvat, D., Galindo, C., Huang, L., McMillin, M., Cooper, B. et al. (2012). Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 61, 268-277.
30. Francis, H., De Morrow, S., Venter, J., Onori, P., White, M., Gaudio, E., Francis, T., Greene, J. F., Jr, Tran, S., Meininger, C. J. et al. (2012). Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut 61, 753-764.
31. Friman, S. (2011). Cholangiocarcinoma - current treatment options. Scand. J. Surg. 100, 30-34.
32. Furge, K. A., Zhang, Y. W. and Vande Woude, G. F. (2000). Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19, 5582-5589.
33. Gaudio, E., Barbaro, B., Alvaro, D., Glaser, S., Francis, H., Ueno, Y., Meininger, C. J., Franchitto, A., Onori, P., Marzioni, M. et al. (2006). Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 130, 1270-1282.
34. Hakamada, K., Sasaki, M., Endoh, M., Itoh, T., Morita, T. and Konn, M. (1997). Late development of bile duct cancer after sphincteroplasty: a ten-to twenty-two-year follow-up study. Surgery 121, 488-492. (Pubitemid 27202893)
35. Han, C. and Wu, T. (2005). Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J. Biol. Chem. 280, 24053-24063. (Pubitemid 40884893)
36. Han, C., Leng, J., Demetris, A. J. and Wu, T. (2004). Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2- independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 64, 1369-1376. (Pubitemid 38235605)
37. Han, J. J., Yu, M., Houston, N., Steinberg, S. M. and Kohn, E. C. (2011). Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol. Oncol. 120, 5-10.
38. Hashim Abdalla, M. S., Taylor-Robinson, S. D., Sharif, A. W., Williams, H. R., Crossey, M. M., Badra, G. A., Thillainayagam, A. V., Bansi, D. S., Thomas, H. C., Waked, I. A. et al. (2011). Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma. HPB (Oxford) 13, 385-390.
39. Hezel, A. F., Deshpande, V. and Zhu, A. X. (2010). Genetics of biliary tract cancers and emerging targeted therapies. J. Clin. Oncol. 28, 3531-3540.
40. Hooth, M. J., Coleman, W. B., Presnell, S. C., Borchert, K. M., Grisham, J. W. and Smith, G. J. (1998). Spontaneous neoplastic transformation of WB-F344 rat liver epithelial cells. Am. J. Pathol. 153, 1913-1921. (Pubitemid 28550678)
41. Hughes, N. R., Pairojkul, C., Royce, S. G., Clouston, A. and Bhathal, P. S. (2006). Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes. J. Clin. Pathol. 59, 1073-1078. (Pubitemid 44570330)
42. Ishimura, N., Bronk, S. F. and Gores, G. J. (2004). Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G88-G95. (Pubitemid 38802122)
43. Ishimura, N., Bronk, S. F. and Gores, G. J. (2005). Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 128, 1354-1368. (Pubitemid 40712185)
44. Isomoto, H., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Guicciardi, M. E., Frank, D. A. and Gores, G. J. (2005). Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42, 1329-1338. (Pubitemid 43260035)
45. Isomoto, H., Mott, J. L., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Haan, S. and Gores, G. J. (2007). Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 132, 384-396. (Pubitemid 46108750)
46. Itatsu, K., Zen, Y., Yamaguchi, J., Ohira, S., Ishikawa, A., Ikeda, H., Sato, Y., Harada, K., Sasaki, M., Sasaki, M. et al. (2008). Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum. Pathol. 39, 710-719.
47. Itatsu, K., Sasaki, M., Yamaguchi, J., Ohira, S., Ishikawa, A., Ikeda, H., Sato, Y., Harada, K., Zen, Y., Sato, H. et al. (2009). Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-a. Am. J. Pathol. 174, 829-841.
48. Jaiswal, M., La Russo, N. F., Shapiro, R. A., Billiar, T. R. and Gores, G. J. (2001). Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 120, 190-199. (Pubitemid 32061883)
49. Kang, Y. K., Kim, W. H. and Jang, J. J. (2002). Expression of G1-S modulators (p 53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum. Pathol. 33, 877-883.
50. Karakatsanis, A., Papaconstantinou, I., Gazouli, M., Lyberopoulou, A., Polymeneas, G. and Voros, D. (2011). Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol. Carcinog. (Epub ahead of print).
51. Khan, S. A., Carmichael, P. L., Taylor-Robinson, S. D., Habib, N. and Thomas, H. C. (2003). DNA adducts, detected by 32P postlabelling, in human cholangiocarcinoma. Gut 52, 586-591. (Pubitemid 36363416)
52. Khan, S. A., Thomas, H. C., Davidson, B. R. and Taylor-Robinson, S. D. (2005). Cholangiocarcinoma. Lancet 366, 1303-1314. (Pubitemid 41416587)
53. Khan, S. A., Emadossadaty, S., Ladep, N. G., Thomas, H. C., Elliott, P., Taylor-Robinson, S. D. and Toledano, M. B. (2012). Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J. Hepatol. 56, 848-854.
54. Kim, D. G., Park, S. Y., You, K. R., Lee, G. B., Kim, H., Moon, W. S., Chun, Y. H. and Park, S. H. (2001). Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species color banding. Genes Chromosomes Cancer 30, 48-56.
55. Knuth, A., Gabbert, H., Dippold, W., Klein, O., Sachsse, W., Bitter-Suermann, D., Prellwitz, W. and Meyer Zum Büschenfelde, K. H. (1985). Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J. Hepatol. 1, 579-596. (Pubitemid 15015131)
56. Kobayashi, M., Ikeda, K., Saitoh, S., Suzuki, F., Tsubota, A., Suzuki, Y., Arase, Y., Murashima, N., Chayama, K. and Kumada, H. (2000). Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 88, 2471-2477. (Pubitemid 30331952)
57. Kobayashi, S., Werneburg, N. W., Bronk, S. F., Kaufmann, S. H. and Gores, G. J. (2005). Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128, 2054-2065. (Pubitemid 40824713)
58. Komori, J., Marusawa, H., Machimoto, T., Endo, Y., Kinoshita, K., Kou, T., Haga, H., Ikai, I., Uemoto, S. and Chiba, T. (2008). Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 47, 888-896. (Pubitemid 351449680)
59. Ku, J. L., Yoon, K. A., Kim, I. J., Kim, W. H., Jang, J. Y., Suh, K. S., Kim, S. W., Park, Y. H., Hwang, J. H., Yoon, Y. B. et al. (2002). Establishment and characterisation of six human biliary tract cancer cell lines. Br. J. Cancer 87, 187-193.
60. Kusaka, Y., Tokiwa, T. and Sato, J. (1988). Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res. Exp. Med. (Berl.) 188, 367-375.
61. Lai, G. H. and Sirica, A. E. (1999). Establishment of a novel rat cholangiocarcinoma cell culture model. Carcinogenesis 20, 2335-2340.
62. Lai, G. H., Zhang, Z., Shen, X. N., Ward, D. J., Dewitt, J. L., Holt, S. E., Rozich, R. A., Hixson, D. C. and Sirica, A. E. (2005). erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129, 2047-2057. (Pubitemid 41772979)
63. Lankisch, T. O., Metzger, J., Negm, A. A., Vosskuhl, K., Schiffer, E., Siwy, J., Weismüller, T. J., Schneider, A. S., Thedieck, K., Baumeister, R. et al. (2011). Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53, 875-884.
64. La Russo, N. F., Shneider, B. L., Black, D., Gores, G. J., James, S. P., Doo, E. and Hoofnagle, J. H. (2006). Primary sclerosing cholangitis: summary of a workshop. Hepatology 44, 746-764. (Pubitemid 44433732)
65. Lee, C. H., Chang, C. J., Lin, Y. J., Yeh, C. N., Chen, M. F. and Hsieh, S. Y. (2009a). Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br. J. Cancer 100, 1765-1770.
66. Lee, M. J., Yu, G. R., Yoo, H. J., Kim, J. H., Yoon, B. I., Choi, Y. K. and Kim, D. G. (2009b). ANXA8 downregulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma. Gastroenterology 137, 1138-1150, e1-e9.
67. Leelawat, K., Leelawat, S., Narong, S. and Hongeng, S. (2007). Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J. Gastroenterol. 13, 1561-1568. (Pubitemid 46672665)
68. Leelawat, K., Sakchinabut, S., Narong, S. and Wannaprasert, J. (2009). Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol. 9
69. Leone, F., Cavalloni, G., Pignochino, Y., Sarotto, I., Ferraris, R., Piacibello, W., Venesio, T., Capussotti, L., Risio, M. and Aglietta, M. (2006). Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin. Cancer Res. 12, 1680-1685.
70. Li, Y., Deuring, J., Peppelenbosch, M. P., Kuipers, E. J., De Haar, C. and Van der Woude, C. J. (2012). IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis 33, 1889-1896.
71. Lim, J. H. and Park, C. K. (2004). Pathology of cholangiocarcinoma. Abdom. Imaging 29, 540-547. (Pubitemid 39095752)
72. Melum, E., Karlsen, T. H., Schrumpf, E., Bergquist, A., Thorsby, E., Boberg, K. M. and Lie, B. A. (2008). Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 47, 90-96. (Pubitemid 351171045)
73. Menakongka, A. and Suthiphongchai, T. (2010). Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J. Gastroenterol. 16, 713-722.
74. Meng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., Jiang, J., Schmittgen, T. D. and Patel, T. (2006). Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130, 2113-2129. (Pubitemid 43816961)
75. Meng, F., Henson, R., Wehbe-Janek, H., Smith, H., Ueno, Y. and Patel, T. (2007). The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J. Biol. Chem. 282, 8256-8264. (Pubitemid 47093612)
76. Meng, F., Wehbe-Janek, H., Henson, R., Smith, H. and Patel, T. (2008). Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 27, 378-386.
77. Metzger, J., Negm, A. A., Plentz, R. R., Weismüller, T. J., Wedemeyer, J., Karlsen, T. H., Dakna, M., Mullen, W., Mischak, H., Manns, M. P. et al. (2012). Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 62, 122-130.
78. Miyagiwa, M., Ichida, T., Tokiwa, T., Sato, J. and Sasaki, H. (1989). A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell. Dev. Biol. 25, 503-510. (Pubitemid 19177403)
79. Miyazaki, M., Ohashi, R., Tsuji, T., Mihara, K., Gohda, E. and Namba, M. (1998). Transforming growth factor-beta 1 stimulates or inhibits cell growth via down-or up-regulation of p21/Waf1. Biochem. Biophys. Res. Commun. 246, 873-880. (Pubitemid 28420951)
80. Miyazawa, M., Aikawa, M., Okada, K., Toshimitsu, Y., Okamoto, K., Koyama, I. and Ikada, Y. (2012). Regeneration of extrahepatic bile ducts by tissue engineering with a bioabsorbable polymer. J. Artif. Organs 15, 26-31.
81. Mott, J. L., Kobayashi, S., Bronk, S. F. and Gores, G. J. (2007). mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26, 6133-6140. (Pubitemid 47414372)
82. Nault, J. C. and Zucman-Rossi, J. (2011). Genetics of hepatobiliary carcinogenesis. Semin. Liver Dis. 31, 173-187.
83. Nonomura, A., Ohta, G., Nakanuma, Y., Izumi, R., Mizukami, Y., Matsubara, F., Hayashi, M., Watanabe, K. and Takayanagi, N. (1988). Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 8, 157-166.
84. Nuntagowat, C., Leelawat, K. and Tohtong, R. (2010). NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin. Exp. Metastasis 27, 295-305.
85. Ogasawara, S., Yano, H., Higaki, K., Takayama, A., Akiba, J., Shiota, K. and Kojiro, M. (2001). Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol. Res. 20, 97-113. (Pubitemid 32294098)
86. Papaconstantinou, I., Karakatsanis, A., Gazouli, M., Polymeneas, G. and Voros, D. (2012). The role of microRNAs in liver cancer. Eur. J. Gastroenterol. Hepatol. 24, 223-228.
87. Pollheimer, M. J., Trauner, M. and Fickert, P. (2011). Will we ever model PSC? - "It's hard to be a PSC model!". Clin. Res. Hepatol. Gastroenterol. 35, 792-804.
88. Prakobwong, S., Pinlaor, P., Charoensuk, L., Khoontawad, J., Yongvanit, P., Hiraku, Y. and Pinlaor, S. (2012). The liver fluke Opisthorchis viverrini expresses nitric oxide synthase but not gelatinases. Parasitol. Int. 61, 112-117.
89. Rosen, C. B., Heimbach, J. K. and Gores, G. J. (2010). Liver transplantation for cholangiocarcinoma. Transpl. Int. 23, 692-697.
90. Saijyo, S., Kudo, T., Suzuki, M., Katayose, Y., Shinoda, M., Muto, T., Fukuhara, K., Suzuki, T. and Matsuno, S. (1995). Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J. Exp. Med. 177, 61-71.
91. Sato, Y., Harada, K., Itatsu, K., Ikeda, H., Kakuda, Y., Shimomura, S., Shan Ren, X., Yoneda, N., Sasaki, M. and Nakanuma, Y. (2010). Epithelial-mesenchymal transition induced by transforming growth factor-beta1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am. J. Pathol. 177, 141-152.
92. Sausville, E. A. and Burger, A. M. (2006). Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66, 3351-3354, discussion 3354.
93. Sekiya, S. and Suzuki, A. (2012). Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J. Clin. Invest. 122, 3914-3918.
94. Seol, M. A., Chu, I. S., Lee, M. J., Yu, G. R., Cui, X. D., Cho, B. H., Ahn, E. K., Leem, S. H., Kim, I. H. and Kim, D. G. (2011). Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma. BMC Cancer 11, 78.
95. Shariff, M. I., Gomaa, A. I., Cox, I. J., Patel, M., Williams, H. R., Crossey, M. M., Thillainayagam, A. V., Thomas, H. C., Waked, I., Khan, S. A. et al. (2011). Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J. Proteome Res. 10, 1828-1836.
96. Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M. and Hirohashi, S. (2008). Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135, 1358-1368, e1-e4.
97. Shigehara, K., Yokomuro, S., Ishibashi, O., Mizuguchi, Y., Arima, Y., Kawahigashi, Y., Kanda, T., Akagi, I., Tajiri, T., Yoshida, H. et al. (2011). Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS ONE 6, e23584.
98. Shimonishi, T., Miyazaki, K., Kono, N., Sabit, H., Tuneyama, K., Harada, K., Hirabayashi, J., Kasai, K. and Nakanuma, Y. (2001). Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum. Pathol. 32, 302-310. (Pubitemid 32246805)
99. Sirica, A. E. (2005). Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41, 5-15. (Pubitemid 40066375)
100. Sirica, A. E. (2008). Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J. Gastroenterol. 14, 7033-7058.
101. Sirica, A. E. (2012). The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 9, 44-54.
102. Sirica, A. E., Zhang, Z., Lai, G. H., Asano, T., Shen, X. N., Ward, D. J., Mahatme, A. and Dewitt, J. L. (2008). A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 47, 1178-1190. (Pubitemid 351547904)
103. Sirica, A. E., Dumur, C. I., Campbell, D. J. W., Almenara, J. A., Ogunwobi, O. O. and Dewitt, J. L. (2009). Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin. Gastroenterol. Hepatol. 7 Suppl., S68-S78.
104. Socoteanu, M. P., Mott, F., Alpini, G. and Frankel, A. E. (2008). c-Met targeted therapy of cholangiocarcinoma. World J. Gastroenterol. 14, 2990-2994.
105. Söreide, K., Körner, H., Havnen, J. and Söreide, J. A. (2004). Bile duct cysts in adults. Br. J. Surg. 91, 1538-1548. (Pubitemid 39619915)
106. Sorensen, H. T., Friis, S., Olsen, J. H., Thulstrup, A. M., Mellemkjaer, L., Linet, M., Trichopoulos, D., Vilstrup, H. and Olsen, J. (1998). Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28, 921-925. (Pubitemid 28450250)
107. Sripa, B., Leungwattanawanit, S., Nitta, T., Wongkham, C., Bhudhisawasdi, V., Puapairoj, A., Sripa, C. and Miwa, M. (2005). Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J. Gastroenterol. 11, 3392-3397. (Pubitemid 40873244)
108. Steel, A. W., Postgate, A. J., Khorsandi, S., Nicholls, J., Jiao, L., Vlavianos, P., Habib, N. and Westaby, D. (2011). Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest. Endosc. 73, 149-153.
109. Su, W. C., Shiesh, S. C., Liu, H. S., Chen, C. Y., Chow, N. H. and Lin, X. Z. (2001). Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig. Dis. Sci. 46, 1387-1392.
110. Sugawara, H., Yasoshima, M., Katayanagi, K., Kono, N., Watanabe, Y., Harada, K. and Nakanuma, Y. (1998). Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 33, 145-153. (Pubitemid 28387024)
111. Tadlock, L. and Patel, T. (2001). Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology 33, 43-51. (Pubitemid 32016886)
112. Takiyama, I., Terashima, M., Ikeda, K., Kawamura, H., Kashiwaba, M., Tamura, G., Suto, T., Nakashima, F., Sasaki, R. and Saito, K. (1998). Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (ICBD-1). Oncol. Rep. 5, 463-467. (Pubitemid 28100112)
113. Tanaka, S., Sugimachi, K., Kameyama, T., Maehara, S., Shirabe, K., Shimada, M., Wands, J. R. and Maehara, Y. (2003). Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology 37, 1122-1129. (Pubitemid 36538689)
114. Tang, D., Nagano, H., Yamamoto, H., Wada, H., Nakamura, M., Kondo, M., Ota, H., Yoshioka, S., Kato, H., Damdinsuren, B. et al. (2006). Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol. Rep. 15, 525-532.
115. Tannapfel, A., Benicke, M., Katalinic, A., Uhlmann, D., Köckerling, F., Hauss, J. and Wittekind, C. (2000a). Frequency of p16 (INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47, 721-727.
116. Tannapfel, A., Weinans, L., Geissler, F., Schütz, A., Katalinic, A., Köckerling, F., Hauss, J. and Wittekind, C. (2000b). Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig. Dis. Sci. 45, 317-324. (Pubitemid 30133893)
117. Tannapfel, A., Sommerer, F., Benicke, M., Weinans, L., Katalinic, A., Geissler, F., Uhlmann, D., Hauss, J. and Wittekind, C. (2002). Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J. Pathol. 197, 624-631.
118. Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J. and Wittekind, C. (2003). Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52, 706-712. (Pubitemid 36528874)
119. Tesana, S., Takahashi, Y., Sithithaworn, P., Ando, K., Sakakura, T., Yutanawiboonchai, W., Pairojkul, C. and Ruangjirachuporn, W. (2000). Ultrastructural and immunohistochemical analysis of cholangiocarcinoma in immunized Syrian golden hamsters infected with Opisthorchis viverrini and administered with dimethylnitrosamine. Parasitol. Int. 49, 239-251. (Pubitemid 30665648)
120. Thamavit, W., Pairojkul, C., Tiwawech, D., Itoh, M., Shirai, T. and Ito, N. (1993). Promotion of cholangiocarcinogenesis in the hamster liver by bile duct ligation after dimethylnitrosamine initiation. Carcinogenesis 14, 2415-2417. (Pubitemid 23335203)
121. Tokumoto, N., Ikeda, S., Ishizaki, Y., Kurihara, T., Ozaki, S., Iseki, M., Shimizu, Y., Itamoto, T., Arihiro, K., Okajima, M. et al. (2005). Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int. J. Oncol. 27, 973-980.
122. Tsao, M. S., Smith, J. D., Nelson, K. G. and Grisham, J. W. (1984). A diploid epithelial cell line from normal adult rat liver with phenotypic properties of 'oval' cells. Exp. Cell Res. 154, 38-52. (Pubitemid 14006407)
123. Tyson, G. L. and El-Serag, H. B. (2011). Risk factors for cholangiocarcinoma. Hepatology 54, 173-184.
124. Utispan, K., Thuwajit, P., Abiko, Y., Charngkaew, K., Paupairoj, A., Chau-in, S. and Thuwajit, C. (2010). Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol. Cancer 9, 13.
125. Valle, J. W., Wasan, H., Johnson, P., Jones, E., Dixon, L., Swindell, R., Baka, S., Maraveyas, A., Corrie, P., Falk, S. et al. (2009). Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br. J. Cancer 101, 621-627.
126. Voskoglou-Nomikos, T., Pater, J. L. and Seymour, L. (2003). Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9, 4227-4239. (Pubitemid 37204044)
127. Watanabe, M., Chigusa, M., Takahashi, H., Nakamura, J., Tanaka, H. and Ohno, T. (2000). High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo. In Vitro Cell. Dev. Biol. Anim. 36, 104-109. (Pubitemid 30141617)
128. Werneburg, N. W., Yoon, J. H., Higuchi, H. and Gores, G. J. (2003). Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G31-G36. (Pubitemid 36736385)
129. Wong, N., Li, L., Tsang, K., Lai, P. B., To, K. F. and Johnson, P. J. (2002). Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J. Hepatol. 37, 633-639. (Pubitemid 35305544)
130. Xu, X., Kobayashi, S., Qiao, W., Li, C., Xiao, C., Radaeva, S., Stiles, B., Wang, R. H., Ohara, N., Yoshino, T. et al. (2006). Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J. Clin. Invest. 116, 1843-1852. (Pubitemid 44033309)
131. Yamaguchi, N., Morioka, H., Ohkura, H., Hirohashi, S. and Kawai, K. (1985). Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium. J. Natl. Cancer Inst. 75, 29-35. (Pubitemid 15005951)
132. Yano, H., Maruiwa, M., Iemura, A., Mizoguchi, A. and Kojiro, M. (1992). Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (KMBC). Cancer 69, 1664-1673.
133. Yao, X., Wang, X., Wang, Z., Dai, L., Zhang, G., Yan, Q. and Zhou, W. (2012). Clinicopathological and prognostic significance of epithelial mesenchymal transition-related protein expression in intrahepatic cholangiocarcinoma. OncoTargets Ther. 5, 255-261.
134. Yeh, C. N., Maitra, A., Lee, K. F., Jan, Y. Y. and Chen, M. F. (2004). Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25, 631-636. (Pubitemid 38499952)
135. Yoon, J. H., Canbay, A. E., Werneburg, N. W., Lee, S. P. and Gores, G. J.
136. Yoon, H. A., Noh, M. H., Kim, B. G., Han, J. S., Jang, J. S., Choi, S. R., Jeong, J. S. and Chun, J. H. (2011). Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J. Gastroenterol. 17, 4023-4030.
137. Zabron, A. A., Horneffer-Van der Sluis, V. M., Wadsworth, C. A., Laird, F., Gierula, M., Thillainayagam, A. V., Vlavianos, P., Westaby, D., Taylor-Robinson, S. D., Edwards, R. J. et al. (2011). Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Am. J. Gastroenterol. 106, 1711-1717.
138. Zhang, Z., Lai, G. H. and Sirica, A. E. (2004). Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39, 1028-1037. (Pubitemid 38428942)
139. Zhou, Y. M., Yin, Z. F., Yang, J. M., Li, B., Shao, W. Y., Xu, F., Wang, Y. L. and Li, D. Q. (2008). Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J. Gastroenterol. 14, 632-635. (Pubitemid 351320834)